The Survival of Patients with t(15;17)(q22;q12) Positive Acute Promyelocytic Leukemia: A Study in North-East of Iran.
Acute myeloid leukemia
Acute promyelocytic leukemia
Blood cancer
Survival
t(15;17)(q22;q12)
Journal
Iranian journal of pathology
ISSN: 1735-5303
Titre abrégé: Iran J Pathol
Pays: Iran
ID NLM: 101515128
Informations de publication
Date de publication:
2020
2020
Historique:
received:
27
01
2019
accepted:
09
04
2019
entrez:
6
8
2020
pubmed:
6
8
2020
medline:
6
8
2020
Statut:
ppublish
Résumé
Acute promyelocytic leukemia (APL) with t(15;17)(q22;q12) is a relatively common subtype of acute myeloid leukemia (AML). Here, our objective was to ascertain the survival of patients with this leukemia in north-east of Iran. Survival rates of 42 APL patients with t(15;17)(q22;q12) were assessed. Clinical information was obtained from archived medical records. Statistical analysis was performed by SPSS 18 software using log-ranked test and Kaplan Maier survival analysis. Females and males comprised 49% and 51%, respectively. The mean age at diagnosis was 34.3 Younger age, lower WBC count and higher platelet count were significantly associated with longer survival in AML patients with t(15;17)(q22; q12).
Sections du résumé
BACKGROUND & OBJECTIVE
OBJECTIVE
Acute promyelocytic leukemia (APL) with t(15;17)(q22;q12) is a relatively common subtype of acute myeloid leukemia (AML). Here, our objective was to ascertain the survival of patients with this leukemia in north-east of Iran.
METHODS
METHODS
Survival rates of 42 APL patients with t(15;17)(q22;q12) were assessed. Clinical information was obtained from archived medical records. Statistical analysis was performed by SPSS 18 software using log-ranked test and Kaplan Maier survival analysis.
RESULTS
RESULTS
Females and males comprised 49% and 51%, respectively. The mean age at diagnosis was 34.3
CONCLUSION
CONCLUSIONS
Younger age, lower WBC count and higher platelet count were significantly associated with longer survival in AML patients with t(15;17)(q22; q12).
Identifiants
pubmed: 32754212
doi: 10.30699/ijp.2020.101417.2007
pmc: PMC7354063
doi:
Types de publication
Journal Article
Langues
eng
Pagination
175-181Références
Asian Pac J Cancer Prev. 2016;17(3):1547-51
pubmed: 27039804
Blood. 2012 Dec 6;120(24):4840-5
pubmed: 23071272
Iran J Cancer Prev. 2012 Summer;5(3):157-63
pubmed: 25628835
Ann Oncol. 2001 Apr;12(4):451-5
pubmed: 11398875
Adv Biomed Res. 2013 Jun 29;2:51
pubmed: 24516851
Blood. 2012 Oct 11;120(15):2963-72
pubmed: 22915647
Clin Lymphoma Myeloma Leuk. 2015 Dec;15(12):771-7
pubmed: 26361645
Int J Hematol. 2013 Aug;98(2):197-205
pubmed: 23719676
Ann Hematol. 2016 Apr;95(5):673-80
pubmed: 26920716
N Engl J Med. 2013 Jul 11;369(2):111-21
pubmed: 23841729
Leuk Res. 2007 Jun;31(6):765-71
pubmed: 17007927
Cancer Causes Control. 2009 Oct;20(8):1409-20
pubmed: 19496000
Cell. 2012 Jul 20;150(2):264-78
pubmed: 22817890
Oncotarget. 2016 Nov 1;7(44):71974-71986
pubmed: 27713127
Cancer. 2012 Dec 1;118(23):5811-8
pubmed: 22707337
N Engl J Med. 1991 May 16;324(20):1385-93
pubmed: 1850498
Asian Pac J Cancer Prev. 2015;16(17):7759-63
pubmed: 26625794
Haematologica. 2012 Dec;97(12):1916-24
pubmed: 22773600
J Hematother Stem Cell Res. 2002 Dec;11(6):941-50
pubmed: 12590709
Acta Haematol. 2014;132(3-4):307-12
pubmed: 25228556
Blood. 2012 Jan 5;119(1):34-43
pubmed: 22086414
Cell J. 2016 Spring;18(1):37-45
pubmed: 27054117
J Clin Oncol. 2014 May 20;32(15):1586-94
pubmed: 24711548
Lancet. 2013 Feb 9;381(9865):484-95
pubmed: 23399072
Leuk Lymphoma. 2015;56(10):2787-92
pubmed: 25669926